Muscular Dystrophy Trial, Recruiting (NCT05016908)

Muscular Dystrophy Trial, Recruiting NCT05016908 Sponsor: Massachusetts General Hospital Condition: Muscular Dystrophy

Printed from Voxsanity (voxsanity.com.au) — NCT05016908 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Muscular Dystrophy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) confirmed through genetic testing, or healthy individuals with no known muscular dystrophy (genetic testing may not be required for healthy participants).
People who are able and willing to give written consent or agreement to take part in the study.
For the blood/fluid sample part of the study: males aged 5 years or older with DMD or BMD, or males and females aged 18 years or older without muscular dystrophy.

Who may not be able to join:

People with a medical history of a weakened immune system, blood clotting problems, pre-existing liver or kidney disease, HIV, or hepatitis B and/or C.
People who have taken blood-thinning or anti-clotting medications within 7 to 60 days before the blood draw (the timeframe depends on the type of medication — confirm with trial site).
People who are unable or unwilling to provide written consent to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thurman M. Wheeler, MD, Massachusetts General Hospital

Phone: 617-726-7506

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05016908

Sponsor: Massachusetts General Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Muscular Dystrophy

Trial contact: 617-726-7506

More information: https://clinicaltrials.gov/study/NCT05016908

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) confirmed through genetic testing, or healthy individuals with no known muscular dystrophy (genetic testing may not be required for healthy participants).
People who are able and willing to give written consent or agreement to take part in the study.
For the blood/fluid sample part of the study: males aged 5 years or older with DMD or BMD, or males and females aged 18 years or older without muscular dystrophy.

Who may not be able to join:

People with a medical history of a weakened immune system, blood clotting problems, pre-existing liver or kidney disease, HIV, or hepatitis B and/or C.
People who have taken blood-thinning or anti-clotting medications within 7 to 60 days before the blood draw (the timeframe depends on the type of medication — confirm with trial site).
People who are unable or unwilling to provide written consent to participate.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Massachusetts General Hospital

Registry

ClinicalTrials.gov

Start date

30 November 2019

Est. completion

1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Extracellular RNA in biofluids

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov